ATE145199T1 - Eine physikalische form von n-(4-(5- (cyclopentyloxycarbonylamino)-1-methyl-indol-3- ylmethyl>-3-methoxybenzoyl>-2- methylbenzolsulfonamid, ein verfahren zu dessen herstellung und es enthaltende pharmazeutische zusammensetzungen - Google Patents

Eine physikalische form von n-(4-(5- (cyclopentyloxycarbonylamino)-1-methyl-indol-3- ylmethyl>-3-methoxybenzoyl>-2- methylbenzolsulfonamid, ein verfahren zu dessen herstellung und es enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE145199T1
ATE145199T1 AT91311505T AT91311505T ATE145199T1 AT E145199 T1 ATE145199 T1 AT E145199T1 AT 91311505 T AT91311505 T AT 91311505T AT 91311505 T AT91311505 T AT 91311505T AT E145199 T1 ATE145199 T1 AT E145199T1
Authority
AT
Austria
Prior art keywords
methylbenzenesulfonamid
cyclopentyloxycarbonylamino
methoxybenzoyl
ylmethyl
indole
Prior art date
Application number
AT91311505T
Other languages
English (en)
Inventor
Martin Paul Edwards
John David Sherwood
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of ATE145199T1 publication Critical patent/ATE145199T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT91311505T 1990-12-12 1991-12-11 Eine physikalische form von n-(4-(5- (cyclopentyloxycarbonylamino)-1-methyl-indol-3- ylmethyl>-3-methoxybenzoyl>-2- methylbenzolsulfonamid, ein verfahren zu dessen herstellung und es enthaltende pharmazeutische zusammensetzungen ATE145199T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909027018A GB9027018D0 (en) 1990-12-12 1990-12-12 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
ATE145199T1 true ATE145199T1 (de) 1996-11-15

Family

ID=10686919

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91311505T ATE145199T1 (de) 1990-12-12 1991-12-11 Eine physikalische form von n-(4-(5- (cyclopentyloxycarbonylamino)-1-methyl-indol-3- ylmethyl>-3-methoxybenzoyl>-2- methylbenzolsulfonamid, ein verfahren zu dessen herstellung und es enthaltende pharmazeutische zusammensetzungen

Country Status (28)

Country Link
US (1) US5294636A (de)
EP (1) EP0490649B1 (de)
JP (1) JP2650807B2 (de)
KR (1) KR100194479B1 (de)
CN (2) CN1032469C (de)
AP (1) AP286A (de)
AT (1) ATE145199T1 (de)
AU (1) AU656344B2 (de)
CA (1) CA2056067C (de)
CZ (1) CZ288151B6 (de)
DE (1) DE69123123T2 (de)
DK (1) DK0490649T3 (de)
ES (1) ES2094797T3 (de)
FI (1) FI101296B (de)
GB (2) GB9027018D0 (de)
GR (1) GR3021605T3 (de)
HK (1) HK81497A (de)
HU (2) HU213109B (de)
IE (1) IE914316A1 (de)
IL (1) IL100090A (de)
MX (1) MX9102475A (de)
MY (1) MY108629A (de)
NZ (1) NZ240940A (de)
PH (1) PH30041A (de)
RU (1) RU2107682C1 (de)
SK (1) SK279018B6 (de)
TW (1) TW222264B (de)
ZA (1) ZA919772B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE113581T1 (de) * 1990-05-04 1994-11-15 Ciba Geigy Ag Substituierte indole.
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
IL111080A (en) * 1993-10-01 1999-08-17 Astra Ab Method for treating a finely divided powder medicament
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
EP1855651A4 (de) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen heterocyclischer amidderivate
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
CA2695008A1 (en) * 2007-07-30 2009-02-05 Auspex Pharmaceuticals, Inc. Substituted indoles
TWI469965B (zh) * 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103396353B (zh) * 2013-08-23 2015-05-20 海南通用三洋药业有限公司 一种扎鲁司特无定型态及其制备方法
CA2936332A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
PT109030B (pt) 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
WO2018140858A1 (en) 2017-01-30 2018-08-02 Western New England University Thiol isomerases inhibitors and use thereof
WO2022243942A1 (en) 2021-05-19 2022-11-24 Quercis Pharma AG Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
WO2023214391A1 (en) 2022-05-06 2023-11-09 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives

Also Published As

Publication number Publication date
EP0490649B1 (de) 1996-11-13
FI915825A0 (fi) 1991-12-11
IE914316A1 (en) 1992-06-17
CN1074411C (zh) 2001-11-07
GB2250743B (en) 1995-02-15
HU211125A9 (en) 1995-10-30
FI915825A (fi) 1992-06-13
KR920012031A (ko) 1992-07-25
HU913863D0 (en) 1992-02-28
GB2250743A (en) 1992-06-17
RU2107682C1 (ru) 1998-03-27
GB9027018D0 (en) 1991-01-30
HUT60717A (en) 1992-10-28
CA2056067A1 (en) 1992-06-13
AU656344B2 (en) 1995-02-02
DE69123123T2 (de) 1997-03-06
JP2650807B2 (ja) 1997-09-10
DE69123123D1 (de) 1996-12-19
JPH04266872A (ja) 1992-09-22
HU213109B (en) 1997-02-28
MY108629A (en) 1996-10-31
CA2056067C (en) 2001-09-04
ZA919772B (en) 1992-09-30
DK0490649T3 (da) 1997-04-21
ES2094797T3 (es) 1997-02-01
IL100090A (en) 1996-09-12
CN1032469C (zh) 1996-08-07
US5294636A (en) 1994-03-15
PH30041A (en) 1996-11-08
AP9100341A0 (en) 1992-01-31
GR3021605T3 (en) 1997-02-28
FI101296B1 (fi) 1998-05-29
AU8899591A (en) 1992-06-18
CN1063100A (zh) 1992-07-29
KR100194479B1 (ko) 1999-06-15
IL100090A0 (en) 1992-08-18
CS375891A3 (en) 1992-06-17
CZ288151B6 (en) 2001-05-16
EP0490649A1 (de) 1992-06-17
HK81497A (en) 1997-06-27
NZ240940A (en) 1994-05-26
GB9126353D0 (en) 1992-02-12
MX9102475A (es) 1992-06-01
SK279018B6 (sk) 1998-05-06
FI101296B (fi) 1998-05-29
AP286A (en) 1993-09-26
CN1148491A (zh) 1997-04-30
TW222264B (de) 1994-04-11

Similar Documents

Publication Publication Date Title
ATE145199T1 (de) Eine physikalische form von n-(4-(5- (cyclopentyloxycarbonylamino)-1-methyl-indol-3- ylmethyl>-3-methoxybenzoyl>-2- methylbenzolsulfonamid, ein verfahren zu dessen herstellung und es enthaltende pharmazeutische zusammensetzungen
DE69131627D1 (de) Dialkoxypyridinylbenzimidazolderivate, verfahren zur herstellung und ihre pharmazeutische verwendung
DE69007069D1 (de) Kniescheibenprothese und Verfahren zu deren Herstellung.
ATE296823T1 (de) Substituierte heterocyclische verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
DE69006290D1 (de) N-Substituierte Benzyloxyiminderivate, Verfahren zu deren Herstellung und deren Verwendung.
DE3585100D1 (de) N-aryl-n-(4-piperidinyl)amide und pharmazeutische zusammensetzungen und verfahren unter verwendung dieser verbindungen.
ATA315488A (de) Neue adenosinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische praeparate
DE68926448D1 (de) Bildsensor und verfahren zu dessen herstellung
DE3775294D1 (de) Implantatwerkstoff und verfahren zu seiner herstellung.
DE69124769D1 (de) Verfahren zur Herstellung von (1'R,3S)-3-(1'-hydroxy-ethyl)-Azetidin-2-on und deren Derivaten
DE3888527D1 (de) Biologisch abbaubare und resorbierbare chirurgische materialien und verfahren zu deren herstellung.
ATE56956T1 (de) (s)-(-)-1-propyl-2',6'-pipecoloxylididhydrochloridmonohydrat, verfahren zu seiner herstellung und es enthaltendes pharmazeutisches praeparat.
DE58901243D1 (de) Titandioxid, verfahren zu seiner herstellung und dessen verwendung.
DE3777122D1 (de) Alkansulfonanilid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69022023D1 (de) Filmkondensator und verfahren zu seiner herstellung.
DE58903737D1 (de) Flaechenlager und verfahren zu seiner herstellung.
DE69111327D1 (de) Block von Mikroverbindungsstiften und Verfahren zu dessen Herstellung.
ATE211911T1 (de) Tiagabinhydrochlorid enthaltendes arzneimittel und verfahren zu dessen herstellung
ATE94764T1 (de) Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung.
ATA95690A (de) Thieno-triazolo-diazepinderivate, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE59510180D1 (de) Verfahren zur Herstellung von 4-Amino-2,2,6,6-tetramethyl-piperidin
DE3767894D1 (de) 1,2-dithiol-3-thion-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellung.
DE59105224D1 (de) Verfahren zur Herstellung von N-substituierten Pyrrolidonen.
ATA30594A (de) Gereinigte form von streptograminen, ihre herstellung und sie enthaltende pharmazeutische massen
ATA56690A (de) Sulfonylderivate der thieno-triazolo-diazepine, verfahren zu deren herstellung und sie enthaltendetherapeutische zusammensetzungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee